ISSN: 2642-6250
Authors: Yavari M, Afshar MM, Jabalameli F, kharkani PS, Jafari NM, kharkani SS, Eskandarian Z, Kamyar G, Esmaeili H* and Ahmadzada M
SARS-CoV-2 infection can have a severe evolution and complications in people who present comorbidities. Indeed, people with diabetes, especially those with type 1, and COVID19 are exposed to and an increased risk of diabetic ketoacidosis. Also cardiac complications due to coronary heart disease or other cardiovascular one, such as hypertension, are possible. These complications may be caused by the virus entering into cardiomyocytes or even other surrounding cells. In people with fatty liver/hepatic impairment and COVID-19, there is an increased expression of ACE2 receptors through the HEK293 cell line, which allows SARS-CoV-2 to enter the cells through the TMPRSS2 interface with the help of the regulatory protein PIKFYE, by therefore increasing the severity of the disease. Moreover SARS-CoV-2 after entry causes T-cell CD8 + reaction, which leads to liver cell damage. The incidence of COVID-19 seems to be high in people with blood group A and low in those with blood group 0. For these reason, the aim of this review is to summarize evidence of main metabolic comorbidities (diabetes, cardiovascular diseases, and liver diseases) and blood groups and COVID-19.
Keywords: Coivd-19; Diabetes; ACE2 Receptors; United Kingdom
